| Real-world validation of molecular international prognostic scoring system for myelodysplastic syndromes E Sauta, M Robin, M Bersanelli, E Travaglino, M Meggendorfer, LP Zhao, ... Journal of Clinical Oncology 41 (15), 2827-2842, 2023 | 49 | 2023 |
| Synthetic data generation by artificial intelligence to accelerate research and precision medicine in hematology S D'amico, D Dall’Olio, C Sala, L Dall’Olio, E Sauta, M Zampini, G Asti, ... JCO Clinical Cancer Informatics 7, e2300021, 2023 | 15 | 2023 |
| Fludarabine, high-dose cytarabine and idarubicin-based induction may overcome the negative prognostic impact of FLT3-ITD in NPM1 mutated AML, irrespectively of FLT3-ITD allelic … P Minetto, A Candoni, F Guolo, M Clavio, ME Zannier, M Miglino, ... Cancers 13 (1), 34, 2020 | 14 | 2020 |
| Volume balance in chronic kidney disease: evaluation methodologies and innovation opportunities E La Porta, L Lanino, M Calatroni, E Caramella, A Avella, C Quinn, ... Kidney and Blood Pressure Research 46 (4), 396-410, 2021 | 12 | 2021 |
| A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study G Maggioni, M Bersanelli, E Travaglino, AA Piérola, A Kasprzak, ... The Lancet Haematology 10 (2), e117-e128, 2023 | 7 | 2023 |
| Real‐world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts L Lanino, F Restuccia, A Perego, M Ubezio, B Fattizzo, M Riva, ... American Journal of Hematology 98 (8), E204-E208, 2023 | 6 | 2023 |
| Case report: atypical manifestations associated with FOXP3 mutations. The “Fil Rouge” of Treg between IPEX features and other clinical entities? M Gentile, M Miano, P Terranova, S Giardino, M Faraci, F Pierri, E Drago, ... Frontiers in Immunology 13, 854749, 2022 | 3 | 2022 |
